Ophthalmologists growing dissatisfied with EHRs

Ophthalmologists are becoming increasingly dissatisfied with electronic health records (EHRs) as their perceptions of financial and clinical productivity decline, according to a study published in JAMA Ophthalmology.

In this study, researchers evaluated the results of three surveys examining perceptions toward EHRs by ophthalmologists. Members of the American Academy of Ophthalmology were included in the surveys, which included 592 respondents to a 2006 survey, 492 in 2011 and 348 in 2016.

Of all participants, 72.1 percent had implemented EHRs, a 19 percent increase from 2006. While only 15 percent of respondents in 2006 believed that EHR implementation reduced productivity, more than half of respondents believed the same in 2016. Additionally, 13 percent of respondents in 2006 believed EHRs increase costs, which increased to 75 percent in 2016.

"Our findings highlight the fact that companies that design EHR systems should further address the efficiency and usability of those systems," said lead author Michele C. Lim, vice chair and medical director of the University of California, Davis Eye Center. "The surveys reveal deepening dissatisfaction with utilizing EHR. Despite their dissatisfaction, however, only one-third of ophthalmologists surveyed said that they would return to paper records if they could, and more than half said they would not."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.